Inventor · disambiguated record
Armand Bensussan
Also filed as: BENSUSSAN ARMAND
20 granted patents·30 pending applications·151 citations·filing 2001–2025
94Inventor score
Files withINST NAT SANTE RECH MED28OREGA BIOTECH7BENSUSSAN ARMAND6BELIN MARIE-FRANCOISE2ALDERAAN BIOTECHNOLOGY1
Top patents by PatentIndex Score
50 records- 0191US7736647B2Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cellsMONOCLONAL ANTIBODIES THERAPEU·Filed 2005·Granted Jun 15, 2010·28 cites·12 claims
- 0290US7919085B2Means for the diagnosis and therapy of CTCLINST NAT SANTE RECH MED·Filed 2008·Granted Apr 5, 2011·14 cites·4 claims
- 0389US7700102B2Nucleic acids encoding CD100 moleculesDANA FARBER CANCER INST INC·Filed 2002·Granted Apr 20, 2010·23 cites·6 claims
- 0488US10662253B2Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activityINST NAT SANTE RECH MED·Filed 2015·Granted May 26, 2020·5 cites·6 claims
- 0587US8409573B2Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cellsBOUMSELL LAURENCE·Filed 2006·Granted Apr 2, 2013·14 cites·5 claims
- 0686US8518655B2Means for the diagnosis and therapy of CTCLBENSUSSAN ARMAND·Filed 2012·Granted Aug 27, 2013·9 cites·13 claims
- 0786US8268308B2Means for the diagnosis and therapy of CTCLBENSUSSAN ARMAND·Filed 2011·Granted Sep 18, 2012·10 cites·12 claims
- 0881US11685792B2Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activityINST NAT SANTE RECH MED·Filed 2020·Granted Jun 27, 2023·1 cites·9 claims
- 0981US8067247B2Use of anti-CD100 antibodies for the treatment of inflammatory disorders affecting the central or peripheral nervous systemBELIN MARIE-FRANCOISE·Filed 2004·Granted Nov 29, 2011·25 cites·4 claims
- 1080US7399595B2Means for the diagnosis and therapy of CTCLINST NAT SANTE RECH MED·Filed 2001·Granted Jul 15, 2008·11 cites·17 claims
- 1179US10208124B2Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesisINST NAT SANTE RECH MED·Filed 2015·Granted Feb 19, 2019·4 cites·13 claims
- 1276US10351623B2Antagonists of IL-17 isoforms and their usesOREGA BIOTECH·Filed 2017·Granted Jul 16, 2019·3 cites·11 claims
- 1370US8444978B2Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2BENSUSSAN ARMAND·Filed 2011·Granted May 21, 2013·2 cites·11 claims
- 1465US9676847B2IL-17 antagonist antibodiesOREGA BIOTECH·Filed 2013·Granted Jun 13, 2017·1 cites·33 claims
- 1564US9834601B2Antagonists of IL-17 isoforms and their usesOREGA BIOTECH·Filed 2013·Granted Dec 5, 2017·1 cites·6 claims
- 1661US2025067745A1Cd38 as a biomarker and biotarget in t-cell lymphomasINST NAT SANTE RECH MED·Filed 2023·Application pending·0 cites
- 1759US2010303828A1Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells ActivityINST NAT SANTE RECH MED·Filed 2009·Application pending·0 cites
- 1858US2015004170A1Angiogenic and Immunologic Applications of Anti-CD160 Specific Compounds Obtainable From mAb CL1-R2INST NAT SANTE RECH MED·Filed 2014·Application pending·0 cites
- 1955US2021261686A1Antibodies against human cd39 and use thereofOREGA BIOTECH·Filed 2020·Application pending·0 cites
- 2054US2025388692A1Antibodies having specificity for cd38 and uses thereofINST NAT SANTE RECH MED·Filed 2025·Application pending·0 cites
- 2154US2025231193A1Methods for the diagnosis and treatment of t-cell malignanciesINST NAT SANTE RECH MED·Filed 2023·Application pending·0 cites
- 2253US12319745B2Antibodies having specificity for CD38 and uses thereofINST NAT SANTE RECH MED·Filed 2020·Granted Jun 3, 2025·0 cites·25 claims
- 2353US2009317401A1Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2INST NAT SANTE RECH MED·Filed 2005·Application pending·0 cites
- 2452US2014120110A1ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2BENSUSSAN ARMAND·Filed 2013·Application pending·0 cites
- 2552US2017233468A1Il-17 antagonist antibodiesOREGA BIOTECH·Filed 2017·Application pending·0 cites
- 2651US2024002522A1Anti-cd25 antibodiesINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 2751US2024002521A1Anti-cd25 antibodiesINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 2851US2022119766A1Ex vivo generation of gamma delta foxp3+ regulatory t cells and therapeutic uses thereofINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 2950US2022018835A1Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposesINST NAT SANTE RECH MED·Filed 2019·Application pending·0 cites
- 3050US2024175873A1Methods for the diagnosis and treatment of t cell-lymphomasINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 3150US2025179175A1Anti-cd160 transmembrane isoform antibodiesALDERAAN BIOTECHNOLOGY·Filed 2023·Application pending·0 cites
- 3248US2018291102A1Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomasINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 3347US2023045494A1Combination therapies based on ctla4 and il-17b inhibitorsOREGA BIOTECH·Filed 2021·Application pending·0 cites
- 3447US2010008932A1Use of soluble cd160 to suppress immunityINST NAT SANTE RECH MED·Filed 2007·Application pending·0 cites
- 3546US2016130346A1Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomasINST NAT SANTE RECH MED·Filed 2014·Application pending·0 cites
- 3645US2022281967A1Novel il-17b antibodiesOREGA BIOTECH·Filed 2020·Application pending·0 cites
- 3744US2022251232A1Novel anti-cd25 antibodiesINSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICAL·Filed 2020·Application pending·0 cites
- 3843US2010234294A1Identification of new isoforms of the mhc-class i specific receptor cd160 and uses thereofINST NAT SANTE RECH MED·Filed 2008·Application pending·0 cites
- 3942US2022087233A1Non-human animal models of sézary syndromeINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 4041US11365392B2Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereofINST NAT SANTE RECH MED·Filed 2017·Granted Jun 21, 2022·0 cites·3 claims
- 4141US2013273062A1Antibodies against human cd39 and use thereofBENSUSSAN ARMAND·Filed 2011·Application pending·0 cites
- 4240US11198851B2Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereofINST NAT SANTE RECH MED·Filed 2017·Granted Dec 14, 2021·0 cites·4 claims
- 4340US9045544B2Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesisLE BOUTEILLER PHILIPPE·Filed 2011·Granted Jun 2, 2015·0 cites·1 claims
- 4440US2012027758A1Use of anti-cd100 antibodiesBELIN MARIE-FRANCOISE·Filed 2011·Application pending·0 cites
- 4539US11186635B2Monoclonal antibodies binding to the CD160 transmembrane isoformINST NAT SANTE RECH MED·Filed 2017·Granted Nov 30, 2021·0 cites·14 claims
- 4638US2018201687A1Antibodies having specificity to myosin 18a and uses thereofINST NAT SANTE RECH MED·Filed 2016·Application pending·0 cites
- 4734US2019167791A1Immunotherapeutic uses of ex vivo generated foxp3+ regulatory t cellsINST NAT SANTE RECH MED·Filed 2017·Application pending·0 cites
- 4831US2012288499A1Methods for diagnosis and treatment of cutaneous t cell lymphomasBENSUSSAN ARMAND·Filed 2011·Application pending·0 cites
- 4930US2019151346A1Combinations therapies for the treatment of cancerINSERM INSTITUTE NATIONAL DE LA SANTE ET DE LA RECH MEDICALE·Filed 2017·Application pending·0 cites
- 5029US2018214550A1Methods and pharmaceutical compositions for enhancing nk cell killing activitiesINST NAT SANTE RECH MED·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Armand Bensussan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →